Skip to main content
Advertisement
Advertisement
ALKS
ALKS logo
Alkermes Inc. plc
46.53
USD
Sponsored
-0.50
-1.06%
Nov 16, 16:00 UTC -5
Closed
exchange

After-Market

46.53

0.00
+0.01%

Alkermes Inc. plc (ALKS) Earnings

ALKS Earnings Reports

Positive Surprise Ratio

ALKS beat 35 of 44 last estimates.

80%

Next Report

Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$470.12M
/
-$0.17
Implied change from Q3 26 (Revenue/ EPS)
-2.09%
/
-288.89%
Implied change from Q4 25 (Revenue/ EPS)
+22.25%
/
-160.71%

Alkermes Inc. plc earnings per share and revenue

On Nov 03, 2026, ALKS reported earnings of 0.09 USD per share (EPS) for Q3 26, beating the estimate of -0.07 USD, resulting in a 225.00% surprise. Revenue reached 480.13 million, compared to an expected 472.88 million, with a 1.53% difference. The market reacted with a +1.78% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.17 USD, with revenue projected to reach 470.12 million USD, implying an decrease of -288.89% EPS, and decrease of -2.09% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ALX Oncology Holdings Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-6.31%
logo
Genelux Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.22%
logo
Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%
logo
Eloxx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.58
Actual
-$0.49
Surprise
+16.70%
logo
Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
logo
LeonaBio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.73
Actual
-$0.89
Surprise
-20.35%
logo
Estrella Immunopharma, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.17
Surprise
-108.33%
logo
Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%
logo
Kyntra Bio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.61
Actual
-$3.42
Surprise
+5.49%
logo
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
FAQ
For Q3 2026, Alkermes Inc. plc reported EPS of $0.09, beating estimates by 225%, and revenue of $480.13M, 1.53% above expectations.
The stock price moved up 1.78%, changed from $44.89 before the earnings release to $45.69 the day after.
The next earning report is scheduled for Feb 22, 2027.
Based on -- analysts, Alkermes Inc. plc is expected to report EPS of -$0.17 and revenue of $470.12M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement